Tweet
Bellevue Group AG purchased a new position in shares of Intellia Therapeutics Inc (NASDAQ:NTLA) during the 2nd quarter, Holdings Channel reports. The institutional investor purchased 16,734 shares of the company's stock, valued at approximately $458,000.
Several other large investors have also recently made changes to their positions in the company. ARK Investment Management LLC boosted its stake in shares of Intellia Therapeutics by 25.3% during the 2nd quarter. ARK Investment Management LLC now owns 4,513,584 shares of the company's stock worth $123,492,000 after acquiring an additional 910,608 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Intellia Therapeutics by 0.7% during the 1st quarter. BlackRock Inc. now owns 1,722,962 shares of the company's stock worth $36,338,000 after acquiring an additional 12,015 shares in the last quarter. Chevy Chase Trust Holdings Inc. boosted its stake in shares of Intellia Therapeutics by 11.5% during the 2nd quarter. Chevy Chase Trust Holdings Inc. now owns 655,882 shares of the company's stock worth $17,945,000 after acquiring an additional 67,714 shares in the last quarter. Federated Investors Inc. PA boosted its stake in shares of Intellia Therapeutics by 49.5% during the 1st quarter. Federated Investors Inc. PA now owns 598,100 shares of the company's stock worth $12,614,000 after acquiring an additional 198,100 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Intellia Therapeutics by 42.5% during the 4th quarter. Geode Capital Management LLC now owns 195,925 shares of the company's stock worth $3,765,000 after acquiring an additional 58,411 shares in the last quarter. 60.27% of the stock is currently owned by institutional investors and hedge funds. Get Intellia Therapeutics alerts:
In related news, Director Jean Francois Formela sold 6,686 shares of the company's stock in a transaction that occurred on Monday, July 16th. The stock was sold at an average price of $31.17, for a total value of $208,402.62. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink . 3.20% of the stock is currently owned by corporate insiders. A number of equities research analysts recently issued reports on NTLA shares. ValuEngine raised Intellia Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, June 2nd. BidaskClub lowered Intellia Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, July 26th. Wedbush reaffirmed an "outperform" rating and issued a $36.00 target price on shares of Intellia Therapeutics in a research note on Friday, May 18th. Zacks Investment Research lowered Intellia Therapeutics from a "buy" rating to a "hold" rating in a research note on Tuesday, August 7th. Finally, TheStreet lowered Intellia Therapeutics from a "c-" rating to a "d" rating in a research note on Monday, May 7th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Intellia Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $34.14.
NTLA stock opened at $28.00 on Friday. Intellia Therapeutics Inc has a 1 year low of $15.06 and a 1 year high of $35.99. The company has a market capitalization of $1.20 billion, a P/E ratio of -15.02 and a beta of 2.93.
Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Wednesday, August 1st. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.55) by $0.03. Intellia Therapeutics had a negative return on equity of 31.54% and a negative net margin of 284.56%. The firm had revenue of $7.68 million for the quarter, compared to analyst estimates of $6.39 million. During the same quarter in the prior year, the company earned ($0.45) EPS. Intellia Therapeutics's revenue was up 30.2% on a year-over-year basis. equities analysts forecast that Intellia Therapeutics Inc will post -1.97 earnings per share for the current year.
Intellia Therapeutics Profile
Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.
Featured Story: Stock Symbols and CUSIP Explained
Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics Inc (NASDAQ:NTLA). Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter 